• About Us
    • Company History
  • Services
    • At a Glance
    • In vitro DMPK & Pharmacology
      • Physicochemical Properties
      • Chemical Stability
      • In vitro Binding
      • Metabolic Stability
      • Permeability & Transporter Services
      • Reaction Phenotyping
      • CYP Inhibition
      • CYP Induction
      • Pharmacology Assay Development
      • Customised Laboratory Services
    • PK, Bioanalysis & Metabolite Identification
      • Bioanalysis Overview
      • Bioanalysis Services
      • Metabolite Identification
      • Pharmacokinetics (PK)
      • Metabolite Bulk-Up & Isolation (mg to g)
    • Modelling & Simulation
    • ADME Packages
      • Pharmacokinetics
      • Absorption
      • Oral Exposure
      • Human PK & Dose Prediction
    • Formulation Services
    • Due Diligence
      • Hit/Lead Compounds
      • Clinical Candidate
  • Latest
    • Blog
    • Events
    • News
  • Partners
    • Axis BioServices
    • BioAscent
    • Charnwood Molecular
    • Medicines Discovery Catapult
    • Reach Separations
    • Saretius
    • TherapeutAix
  • Meet The Team
  • Resources
    • Articles
    • Posters
    • Presentations
    • Publications
    • Videos
  • Contact Us
  • Join Us
XenoGesis XenoGesis
  • About Us
    • Company History
  • Services
    • At a Glance
    • In vitro DMPK & Pharmacology
      • Physicochemical Properties
      • Chemical Stability
      • In vitro Binding
      • Metabolic Stability
      • Permeability & Transporter Services
      • Reaction Phenotyping
      • CYP Inhibition
      • CYP Induction
      • Pharmacology Assay Development
      • Customised Laboratory Services
    • PK, Bioanalysis & Metabolite Identification
      • Bioanalysis Overview
      • Bioanalysis Services
      • Metabolite Identification
      • Pharmacokinetics (PK)
      • Metabolite Bulk-Up & Isolation (mg to g)
    • Modelling & Simulation
    • ADME Packages
      • Pharmacokinetics
      • Absorption
      • Oral Exposure
      • Human PK & Dose Prediction
    • Formulation Services
    • Due Diligence
      • Hit/Lead Compounds
      • Clinical Candidate
  • Latest
    • Blog
    • Events
    • News
  • Partners
    • Axis BioServices
    • BioAscent
    • Charnwood Molecular
    • Medicines Discovery Catapult
    • Reach Separations
    • Saretius
    • TherapeutAix
  • Meet The Team
  • Resources
    • Articles
    • Posters
    • Presentations
    • Publications
    • Videos
  • Contact Us
  • Join Us
Latest News

Richard Weaver wins IoD East Midlands Director of the Year Award

June 22, 2019
suecarr 2019-06-22T10:38:38+00:00
Latest News

XenoGesis reports rapid export growth

May 8, 2019
suecarr 2019-05-08T10:41:10+00:00
Latest News

Rachel Hemsley appointed to the BioPartner Advisory Board

May 8, 2019
suecarr 2019-05-08T10:40:11+00:00
Latest News

XenoGesis chosen as CRO partner for Medicines Discovery Catapult Virtual R&D group

May 3, 2019
suecarr 2019-05-03T10:42:14+00:00
Contact Us
XenoGesis Ltd
  • BioCity Nottingham, Pennyfoot Street, Nottingham, Nottinghamshire, NG1 1GF, United Kingdom
  • BioHub, Alderley Park, Alderley Edge, Cheshire, SK10 4TG, United Kingdom
  • Telephone: +44 (0)115 837 0626
  • Email: info@xenogesis.com
Services
  • In vitro DMPK & Pharmacology
  • PK, Bioanalysis & Metabolite Identification
  • Modelling & Simulation
  • ADME Packages
  • Formulation Services
  • Due Diligence
Latest News
  • Richard Weaver wins IoD East Midlands Director of the Year Award
  • XenoGesis reports rapid export growth
  • Rachel Hemsley appointed to the BioPartner Advisory Board
Follow Us

© 2019 XenoGesis | BioCity Nottingham | Pennyfoot Street | Nottingham | NG1 1GF | UK

  • Privacy Policy

Our site uses cookies. Learn more about our use of cookies: cookie policy

I accept